Novelties in the Diagnosis and Treatment of Angioedema - PubMed

Affiliations

• PMID: 27470642
• DOI: 10.18176/jiaci.0087

Free article

Review

Novelties in the Diagnosis and Treatment of Angioedema

M Cicardi et al. J Investig Allergol Clin Immunol. 2016.

Free article

Abstract

Angioedema is defined as local, noninflammatory, self-limiting edema that is circumscribed owing to increased leakage of plasma from the capillaries located in the deep layers of the skin and the mucosae. Two mediators, histamine and bradykinin, account for most cases of angioedema. Angioedema can occur with wheals as a manifestation of urticaria, and this form is frequently allergic. In the present review, we discuss nonallergic angioedema without wheals, which can be divided into 3 acquired and 4 hereditary forms. Histamine is the mediator in acquired angioedema of unknown etiology (idiopathic histaminergic acquired angioedema), whereas in other forms the main mediator is bradykinin. Angioedema can be caused by C1-inhibitor deficiency (C1-INH-hereditary angioedema and C1-INH-acquired angioedema), mutations in coagulation factor XII (FXII-hereditary angioedema), and treatment with angiotensin-converting enzyme inhibitors (ACEI-acquired angioedema). Etiology remains unclear in acquired angioedema (idiopathic nonhistaminergic acquired angioedema) and in 1 type of hereditary angioedema (hereditary angioedema of unknown origin). Several treatments are licensed for hereditary C1-INH deficiency. Plasma-derived and recombinant C1-INHs, the bradykinin receptor blocker icatibant, and the plasma kallikrein inhibitor ecallantide have been approved for on-demand treatment to reverse angioedema symptoms. Attenuated androgen and plasma-derived C1-INH are approved for prophylaxis.

Keywords: Angioedema; Angiotensin-converting enzyme inhibitors; Bradykinin; C1 inhibitor; Coagulation factor XII; Histamine; Urticaria.

Similar articles

• Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients.

  Mansi M, Zanichelli A, Coerezza A, Suffritti C, Wu MA, Vacchini R, Stieber C, Cichon S, Cicardi M. Mansi M, et al. J Intern Med. 2015 May;277(5):585-93. doi: 10.1111/joim.12304. Epub 2014 Sep 27. J Intern Med. 2015. PMID: 25196353

• Bradykinin-mediated diseases.

  Kaplan AP. Kaplan AP. Chem Immunol Allergy. 2014;100:140-7. doi: 10.1159/000358619. Epub 2014 May 22. Chem Immunol Allergy. 2014. PMID: 24925394 Review.

• Nonallergic angioedema: role of bradykinin.

  Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Bas M, et al. Allergy. 2007 Aug;62(8):842-56. doi: 10.1111/j.1398-9995.2007.01427.x. Allergy. 2007. PMID: 17620062 Review.

• Diagnosis and treatment of bradykinin-mediated angioedema: outcomes from an angioedema expert consensus meeting.

  Craig TJ, Bernstein JA, Farkas H, Bouillet L, Boccon-Gibod I. Craig TJ, et al. Int Arch Allergy Immunol. 2014;165(2):119-27. doi: 10.1159/000368404. Epub 2014 Nov 15. Int Arch Allergy Immunol. 2014. PMID: 25401373

• Bradykinin-mediated angioedema.

  Obtułowicz K. Obtułowicz K. Pol Arch Med Wewn. 2016;126(1-2):76-85. doi: 10.20452/pamw.3273. Pol Arch Med Wewn. 2016. PMID: 26842379 Review.

Cited by

• Consensus on diagnosis and management of Hereditary Angioedema in the Middle East: A Delphi initiative.

  Maurer M, Abuzakouk M, Al-Ahmad M, Al-Herz W, Alrayes H, Al-Tamemi S, Arnaout R, Binghadeer H, Gutta R, Irani C, Mobayed H, Nasr I, Shendi H, Zaitoun F. Maurer M, et al. World Allergy Organ J. 2022 Dec 24;16(1):100729. doi: 10.1016/j.waojou.2022.100729. eCollection 2023 Jan. World Allergy Organ J. 2022. PMID: 36601261 Free PMC article.

• Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate.

  Bork K, Staubach-Renz P, Hardt J. Bork K, et al. Orphanet J Rare Dis. 2019 Mar 13;14(1):65. doi: 10.1186/s13023-019-1043-3. Orphanet J Rare Dis. 2019. PMID: 30866985 Free PMC article.

• Short-term prophylaxis in patients with angioedema due to C1-inhibitor deficiency undergoing dental procedures: An observational study.

  Zanichelli A, Ghezzi M, Santicchia I, Vacchini R, Cicardi M, Sparaco A, Donati G, Ranìa V, Busa A. Zanichelli A, et al. PLoS One. 2020 Mar 12;15(3):e0230128. doi: 10.1371/journal.pone.0230128. eCollection 2020. PLoS One. 2020. PMID: 32163480 Free PMC article.

• Risk of drug-induced angioedema: a pharmacovigilance study of FDA adverse event reporting system database.

  Fan M, Niu K, Wu X, Shi H. Fan M, et al. Front Pharmacol. 2024 Jul 16;15:1417596. doi: 10.3389/fphar.2024.1417596. eCollection 2024. Front Pharmacol. 2024. PMID: 39081961 Free PMC article.

• The complement system as a potential therapeutic target in rheumatic disease.

  Trouw LA, Pickering MC, Blom AM. Trouw LA, et al. Nat Rev Rheumatol. 2017 Sep;13(9):538-547. doi: 10.1038/nrrheum.2017.125. Epub 2017 Aug 10. Nat Rev Rheumatol. 2017. PMID: 28794515 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Esmon Publicidad

• Other Literature Sources

  • scite Smart Citations